

Paper No. _____
Filed: July 29, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC,
MYLAN PHARMACEUTICALS INC., and MYLAN INC.,
LUPIN LTD., and LUPIN PHARMACEUTICALS INC.,
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD.,
Patent Owner

Case IPR2015-00903*
U.S. Patent 8,129,431

PATENT OWNER'S UPDATED EXHIBIT LIST

* IPR2015-01871 has been joined with this proceeding.

Further to 37 C.F.R. § 42.63(e), Patent Owner Senju Pharmaceutical Co., Ltd., hereby submits a current listing of Senju Exhibits to counsel for Petitioner InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC, Mylan Pharmaceuticals Inc., Mylan Inc., Lupin Ltd., and Lupin Pharmaceuticals Inc. Public versions of Exhibits 2082, 2096, 2105, 2114, 2130, 2220, 2226, 2249, 2271, 2272, and 2273 were filed and served via email to counsel of record for the Petitioner. Confidential versions of Exhibits 2096, 2102, 2103, 2110, 2116, 2130, and 2273, were filed as “BOARD AND PARTIES ONLY” and served on counsel that executed the Acknowledgment Form of the Proposed Stipulated Protective Order.

Exhibits	Description
Exhibit 2001	Transcript of Teleconference with the Board, dated April 15, 2015
Exhibit 2002	U.S. Patent No. 8,669,290 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid”
Exhibit 2003	U.S. Patent No. 8,754,131 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid”
Exhibit 2004	U.S. Patent No. 8,871,813 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid”
Exhibit 2005	U.S. Patent No. 8,927,606 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid”
Exhibit 2006	InnoPharma’s Paragraph IV Notice Letter, dated September 19, 2014

Exhibit 2007	InnoPharma's Paragraph IV Notice Letter, dated October 30, 2014
Exhibit 2008	InnoPharma's Paragraph IV Notice Letter, dated March 27, 2015
Exhibit 2009	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893 (D.N.J. November 3, 2014), ECF No. 1
Exhibit 2010	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No.15-cv-03240 (D.N.J. May 8, 2015), ECF No. 1
Exhibit 2011	Consolidated Scheduling Order, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893 (D.N.J. April 16, 2015), ECF No. 30
Exhibit 2012	Amended Scheduling Order, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-00667 (D.N.J. February 27, 2015), ECF No. 63
Exhibit 2013	Prolensa® (bromfenac ophthalmic solution 0.07%) Prescribing Information.
Exhibit 2014	U.S. Patent No. 5,630,793 to Rowe, "Aqueous Ophthalmic Sprays"
Exhibit 2015	Press Release, Bausch + Lomb, "Bausch + Lomb Receives FDA Approval for Prolensa™ (bromfenac ophthalmic solution) 0.07%," dated April 8, 2013
Exhibit 2016	Lupin's Paragraph IV Notice Letter, dated December 19, 2013
Exhibit 2017	Metrics' Paragraph IV Notice Letter, dated June 26, 2014
Exhibit 2018	Paddock's Paragraph IV Notice Letter, dated December 15, 2014
Exhibit 2019	Apotex's Paragraph IV Notice Letter, dated December 10, 2014
Exhibit 2020	Masson <i>et al.</i> , "Stabilisation of ionic drugs through complexation with non-ionic and ionic cyclodextrins," <i>International Journal of Pharmaceutics</i> 164 (1998)
Exhibit 2021	Loftsson <i>et al.</i> , "Pharmaceutical Applications of Cyclodextrins," <i>Journal of Pharmaceutical Sciences</i> 85:10 (1996)

Exhibit 2022	HSBC Global Research Lupin Company Report, February 3, 2014 (available at http://www.lupin.com/pdf/14/20140203%20-%20Lupin%203QFY14%20-%20HSBC.pdf)
Exhibit 2023	Apotex, “All Products” (available at https://www.apotex.com/us/en/products/search.asp?qt=All&qs=&t=All%20Products) (visited December 16, 2015)
Exhibit 2024	Consent Judgment, <i>Senju Pharm. Co., Ltd. et al. v. Apotex Inc. et al.</i> , No. 15-cv-00336 (D.N.J. May 18, 2015), ECF No. 26
Exhibit 2025	U.S. Patent No. 5,856,345 to Doi <i>et al.</i> , “Method for Stabilizing Pranopufen and Stable Liquid Preparation of Pranopufen”
Exhibit 2026	Xibrom® Prescribing Information
Exhibit 2027	Bromday® Prescribing Information
Exhibit 2028	Drugs@FDA, “Listing of FDA-approved bromfenac ophthalmic solution 0.09% products” (available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=BROMFENAC%20SODIUM) (visited December 16, 2015)
Exhibit 2029	Sheryl Gay Stolberg, “New Painkiller is Withdrawn After 4 Deaths,” <i>N.Y. Times</i> , June 23, 1998
Exhibit 2030	Baklayan <i>et al.</i> , “The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model,” <i>Clinical Ophthalmology</i> 2014:8, 1717-1724 (2014)
Exhibit 2031	’431 Patent Prosecution History, Amendment and Remarks, dated January 15, 2009
Exhibit 2032	’431 Patent Prosecution History, Information Disclosure Statement, dated April 8, 2010
Exhibit 2033	’431 Patent Prosecution History, Notice of Allowance, dated December 23, 2011
Exhibit 2034	Hans Schott, “Effect of inorganic additives on solutions of nonionic surfactants – XVI. Limiting cloud points of highly polyoxyethylated surfactants,” <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> 186, 129-136 (2001)
Exhibit 2035	Transcript of Teleconference with the Board, dated

	December 11, 2015
Exhibit 2036	James Knittel and Robin Zavod, "Drug Design and Relationship of Functional Groups to Pharmacologic Activity," in David A. Williams and Thomas L. Lemke eds. <i>Foye's Principles of Medicinal Chemistry</i> . 5th ed. (Lippincott Williams & Wilkins, 2002) 37-67
Exhibit 2037	W. D. Motherwell <i>et al.</i> , "Crystal Structure Prediction of Small Organic Molecules: A Second Blind Test," <i>Acta Crystallographica Section B</i> . Vol. 58, 2002, 647-661
Exhibit 2038	G. Marc Loudon, <i>Organic Chemistry</i> . 2nd ed. Menlo Park: Benjamin/Cummings, 1988, 1051-1055
Exhibit 2039	New Drugs in Japan Translation
Exhibit 2040	Christopher A. Lipinski <i>et al.</i> , "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings," <i>Advanced Drug Delivery Reviews</i> Vol. 23, 1997, 3-25
Exhibit 2041	Andrew Streitwieser and Clayton H. Heathcock, <i>Introduction to Organic Chemistry</i> , 3rd ed. (Macmillan, 1985) 696-697
Exhibit 2042	Andrew Streitwieser and Clayton H. Heathcock, <i>Introduction to Organic Chemistry</i> , 3rd ed. (Macmillan, 1985) 456-458
Exhibit 2043	D. Attwood and A. T. Florence, "Pharmaceutical Aspects of Solubilization," <i>Surfactant Systems: Their Chemistry, Pharmacy, and Biology</i> (Chapman and Hall, 1983) 293-387
Exhibit 2044	Drugs@FDA, Voltaren [®]
Exhibit 2045	Ronald Breslow and Peter Cambell, "Selective Aromatic Substitution Within A Cyclodextrin Mixed Complex," <i>Communications to the Editor</i> , Received February 14, 1969
Exhibit 2046	Masami Sawada <i>et al.</i> , "Measurement of Chiral Amino Acid Discrimination by Cyclic Oligosaccharides: A Direct FAB Mass Spectrometric Approach," <i>Chemical Communications</i> , 1998, 1453-1454
Exhibit 2047	Samik K. Hait and Satya P. Moulik, "Determination of Critical Micelle Concentration (CMC) of Nonionic Surfactants by Donor-Acceptor Interaction with Iodine and Correlation of CMC with Hydrophile-Lipophile Balance and Other Parameters of the Surfactants," <i>Journal of Surfactants and Detergents</i> Vol. 4 No. 3, 2001, 303-309

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.